Governance Altimmune, Inc.

ALT

US02155H2004

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2026-01-21 EST			5-day change	1st Jan Change
4.620 ^USD	+9.22%		+10.53%	+27.98%

01-05	Altimmune, Inc. Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH	CI
01-05	Altimmune Says US FDA Grants Breakthrough Therapy Designation for Pemvidutide in MASH	MT

Executive Committee: Altimmune, Inc.

Manager

Positions heldSince

Jerome Durso

58 year

Chief Executive Officer	2025-12-31
President	2025-12-31

Randy Brown

Chief Tech/Sci/R&D Officer

J. Rex Horton

57 year

General Counsel

Gregory Weaver

70 year

Comptroller/Controller/Auditor	2024-11-10
Director of Finance/CFO	2024-11-10

Andrew Shutterly

38 year

Comptroller/Controller/Auditor

2023-01-31

Anthony Blandin

Compliance Officer

2022-01-31

Bertrand Georges

Chief Tech/Sci/R&D Officer

2015-02-28

M. Roberts

67 year

Chief Tech/Sci/R&D Officer

2012-11-30

Christophe Arbet-Engels

64 year

Chief Tech/Sci/R&D Officer

2025-09-30

Composition of the Board of Directors: Altimmune, Inc.

Director

CommitteesSince

Jerome Durso

58 year

Chairman

2025-08-11

Catherine Sohn

72 year

Compensation Committee	2011-12-31
Governance Committee	2023-03-22
Nominating Committee	2023-03-22
Governance Committee Chair	2020-12-31
Nominating Committee Chair	2020-12-31

Mack Gill

74 year

Audit Committee	2004-07-31
Governance Committee	2004-07-31
Nominating Committee	2004-07-31

Wayne Pisano

71 year

Audit Committee	2018-08-29
Governance Committee Chair	2018-08-29
Nominating Committee Chair	2018-08-29

Klaus Schafer

76 year

Audit Committee	2017-05-03
Compensation Committee

Philip Hodges

58 year

Compensation Committee	2017-05-03
Audit Committee Chair	2003-08-31

Diane Jorkasky

74 year

Compensation Committee

2020-07-10

Mitchel Sayare

78 year

Director/Board Member	2025-08-11
Independent Dir/Board Member	2010-03-31

Teri Lawver

59 year

Director/Board Member	2025-02-23
Independent Dir/Board Member

Latest Appointments: Altimmune, Inc.

12-01	Altimmune, Inc. Announces CEO Changes	CI
12-01	Altimmune, Inc. Announces Executive Changes	CI
12-01	Altimmune CEO Vipin Garg to Step Down	MT
12-01	Altimmune announces CEO transition, succession plan	RE
11-10	Celldex Therapeutics, Inc. Announces Executive Changes	CI
11-06	Altimmune, Inc. Announces Appointment of Robin Abrams, J.D., as Chief Legal Officer	CI
25-09-29	Altimmune, Inc. Announces the Appointment of Christophe Arbet-Engels as Chief Medical Officer, Effective October 1, 2025	CI

More news

Former Officers and Directors: Altimmune, Inc.

Insider

Positions held

SinceUntil

Vipin K. Garg

Director/Board Member	2018-11-29	2025-12-31
Chief Executive Officer	2018-11-29	2025-12-31
President	2018-11-29	2025-12-31

M. Harris

Chief Tech/Sci/R&D Officer

2019-09-08

2025-09-30

David Drutz

Director/Board Member	2017-04-30	2024-09-25
Chairman	2011-09-30	2017-04-30
Independent Dir/Board Member	2009-12-31	2024-09-25

Richard Eisenstadt

Comptroller/Controller/Auditor	2021-12-30	2024-06-26
Director of Finance/CFO	2021-12-30	2024-06-26
Investor Relations Contact	2021-12-30	2024-06-26
Corporate Secretary	2021-12-30	2024-06-26

Dakshina Reddy

General Counsel

2022-03-31

2024-02-29

Kent Tapper

Comptroller/Controller/Auditor

2015-05-31

2023-01-31

Jose Ochoa

Corporate Officer/Principal

2018-07-09

2022-12-31

William Brown

Comptroller/Controller/Auditor	2018-05-07	2021-12-30
Director of Finance/CFO	2018-05-07	2021-12-30
Investor Relations Contact	2018-05-07	2021-12-30
Public Communications Contact	2018-05-07	2021-12-30
Corporate Secretary	2018-05-07	2021-12-30

Sybil Tasker

Chief Tech/Sci/R&D Officer

2017-05-03

2019-06-29

William Enright

Director/Board Member	2007-12-31	2018-11-29
Chief Executive Officer	-	2018-11-29
President	-	2018-11-29

Elizabeth Czerepak

Director of Finance/CFO	2015-03-31	2018-05-07
Corporate Secretary	2015-03-31	2018-05-07

Philip MacNeill

Director of Finance/CFO	2015-04-30	2017-05-03
Corporate Secretary	2015-04-30	2017-05-03
Treasurer	2015-04-30	2017-05-03

Derace L. Schaffer

Director/Board Member	2005-03-31	-
Independent Dir/Board Member	2005-03-31	-

Ori Solomon

General Counsel

Stacey L. Jurchison

Investor Relations Contact

Age distribution of managers

Parity Men Women

Male	17
Female	3

Of which Executive Committee

Male	9
Female	0

Of which Directors

Male	8
Female	1

Revisions

Révisions CA 1 an

Révisions CA 4 mois

Révisions CA 1 mois

Révisions BNA 1 an

Révisions BNA 4 mois

ESG MSCI

Environnement

Social

Gouvernance

Polémique

Controverses Ethiques

Controverses sur les droits de l'Homme

Controverses Subventions fiscales

Conforme à la finance Islamique

Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. The Company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). The Company has completed the MOMENTUM Phase II obesity trial and is being studied in the IMPACT Phase IIb MASH trial. It is also developing HepTcell, an immunotherapeutic product candidate for patients chronically infected with the hepatitis B virus (HBV). The Company has completed the enrollment in its Phase II clinical trial of HepTcell. Its product candidates are based on its proprietary platform technologies, such as EuPort-based Peptide Technology and Synthetic Peptide Technology-Densigen. The Companyâs wholly owned subsidiaries include Altimmune, LLC, Altimmune UK, Limited, Spitfire Pharma, LLC and Altimmune AU Pty, Limited.

Employees

Sector

Biotechnology & Medical Research

Calendar

03-25 - Q4 2025 Earnings Release (Projected)

More about the company